IJCRR - 5(6), March, 2013
EFFECT OF ANTI-PROGESTROGEN ON THE EPITHELIAL CELL HEIGHT OF RAT ENDOMETRIUM
Author: Khadija Qamar, Samina Anjum, Zarmina Saga
Objective: To investigates the effect of mifepristone on height of the epithelial cells of the endometrium. Study Design: Laboratory based randomized controlled trials Place & Duration of the study: Department of Anatomy, Army Medical College Rawalpindi from Jan. 2007-march 2007. Method: Sixty adult female rats were divided randomly into two groups, comprising of 30 animals in each group. In group A one ml of normal saline was given orally daily for three months while in group B mifepristone was given orally in a dose of 1 mg/kg body weight daily for three months. Results: In the experimental group reduction was observed in epithelial cell height. Significantly lower level of progesterone while higher level of estrogen level in experimental group was noted as compared to the control group. Conclusion: Long term mifepristone administration suppresses the endometrial proliferation and epithelium height was decreased. It also lowered the plasma concentration of progesterone. While the plasma concentration of the estrogen was raised
Keywords: Mifepristone, estrogen, progesterone, epithelium
Khadija Qamar, Samina Anjum, Zarmina Saga. EFFECT OF ANTI-PROGESTROGEN ON THE EPITHELIAL CELL HEIGHT OF RAT ENDOMETRIUM International Journal of Current Research and Review. 5(6), March, 46-50
1. Connelly OM. Female Steroid Hormone Action. Endocrinology 2001; 142(6): 2194- 99.
2. Benakanakere C, Besch-Williford M, Ellersieck R, Hyder SM. Regression of progestin-accelerated7, 12-dimethylbenz[a] anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Endocr Relat Cancer March 1, 2009; 16(1): 85-98.
3. Antoniou G, Kalogirou D, Karakitsos P.Transdermal estrogen with a levonorgestrel- releasing intrauterine device for climacteric complaints versus estradiolreleasing vaginal ring with a vaginal progesterone suppository. Clinical and endometrial responses. Maturitas. 1997; 26: 103-11.
4. De Vivo I, Hankinson SE, Colditz GA, Hunter DJ. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 2003; 63: 5236–8.
5. Gopalkrishnan K, Katkam RR, Sachdeva G, KholKute SD, Padwal V, Puri CP. Effects of an Antiprogestin Onapristone on the Endometrium of Bonnet Monkeys: Morphometric and Ultra Structural Studies. Biol Reprod 1959; 68(6): 779-87.
6. Brenner RM, Slayden OD. Estrogen action in the endometrium and oviduct of rhesus monkeys during RU 486 treatment. In: Beier HM, Spitz IM, editors. Progesterone antagonists in reproductive medicine and oncology. Cary, NC: Oxford University Press; 1994; p.82-97.
7. Jeffrey R. Goldberg, MD; Marcus G. Plescia, MD, MPH; Geraldine D. Anastasio. Mifepristone (RU 486) Current Knowledge and Future Prospects. Arch Fam Med. 1998; 7:219-222.
8. Van Look PFA, Ven herizen H. Post ovulatory methods of fertility regulation: the emergence of antiprogestens. In: Van Look PFA, Perez – Polacies G, editors. Contraceptive research and development. New Delhi: Oxford University Press; 1994; P. 151-201.
9. Baird DT, Glasier AF. Science, medicine and the future: contraception. Br Med J 1999; 319: 969-72.
10. Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol. 1989; 73: 606-12.
11. Maxson WS. The use of progesterone in the treatment of PMS. Clin Obstet Gynecol. 1987; 30: 465-77.
12. Schaison G, George M, Lestrat N, Reinberg A, Baulieu EE. Effects of the antiprogesterone steroids RU 486 during midluteal phase in normal woman. J Clin Endocrinol Metab 1985; 61: 480-9.
13. Murphy AA, Castellano PZ. RU 486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr Opin obstet Gynecol 1994; 6(3): 269-78.
15. O.D. Slayden, M.B. Zelinski, K. Chwalisz, H. Hess-Stumpp, R.M. Brenner Chronic progesterone antagonist–estradiol therapy suppresses breakthrough bleeding and endometrial proliferation in a menopausal macaque model .Hum. Reprod. (2006) 21(12): 3081-3090
16. Chwalisz K, Hsiu JG, Williams RT, Hodgen GD. Evaluation of the antiproliferative actions of the progesterone antagonist’s Mifepristone and onapristone on primate endometruim. Proceeding of the 39th Annual Meeting of the society for Gynecologic Investigation; Texas, USA. Mar 1992; p12-8.
17. S. Schäfer-Somi, O.A. Aksoy, H.B. Beceriklisoy, A. Einspanier, H.O. Hoppen S. Aslan Repeated induction of abortion in bitches and the effect on plasma concentrations of relaxin, progesterone and estradiol-17β. 2007;68: 889-895
18. Ishwad PC, Katkam RR, Hinduja IN, Chwalisz K, Elger W, Puri CP. Treatment with a progesterone antagonist ZR>98.299 delays endometrial development without blocking ovulation in bonnet monkeys. Contraception 1993; 48: 57-70.
19. Sitruk-Ware R. Approval of Mifepristone (RU486) in Europe. Zentraibl Gynakol 2000; 122(5): 241-7.